ASH 2020 | A retrospective study of venetoclax re-treatment in CLL patients
Meghan Thompson, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses a retrospective study of venetoclax re-treatment for chronic lymphocytic leukemia (CLL) patients following progression or relapse after an initial venetoclax-based regimen. A cohort of patients with history of previous CLL treatment, including those previously treated with BTK inhibitors, was identified and their overall response rate to venetoclax re-treatment was found to be 72.2%. This line of treatment was also found to have an encouraging safety profile, suggesting it may be a viable option for CLL patients requiring further therapy. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Curio Science
